What is AuroLase® therapy?
The FDA-approved pilot study will evaluate AuroLase® Therapy, a new treatment that uses a system of near-infrared energy from a laser to heat up nanoparticles that are delivered to the tumor via the blood stream. The nanoparticles, called AuroShells, are absorbed by the tumor but are not absorbed by healthy tissue. The particles are engineered to convert infrared light into heat, thermally destroying the tumor with minimal damage to surrounding tissue.
AuroLase® therapy for lung cancer
Cancer Treatment Centers of America® (CTCA) at Eastern is the first hospital in the U.S. to conduct a clinical trial using advanced nanotherapy for the investigational treatment of primary and metastatic cancerous tumors in the lung.
This clinical trial is designed to evaluate whether or not this approach is effective for the treatment of advanced lung tumors resulting from either primary lung cancer or metastatic tumors in the lung. The trial will be conducted by Dr. Mark Lund and the Interventional Pulmonology Department at Eastern.
“The use of heat to destroy malignant tumors is not new to cancer care, but this technology holds the promise of offering new and exciting treatment options for tumor destruction with minimal collateral damage to adjacent tissue and structures,” said Dr. Mark Lund, Director of Interventional Pulmonology, Bronchoscopy & ICU and the Advanced Center for Lung and Thoracic Oncology at CTCA in Philadelphia. “We are excited about participating in this clinical trial and contributing our experiences and treatment results to others to determine the long-term viability of the treatment.”
The AuroLase Therapy process involves infusing a single dose of nanoshell particles into the patient’s blood stream via intravenous injection. After 12 to 24 hours, enough time for the particles to accumulate inside the tumor, a special laser is used to illuminate and heat the particles within the tumor. Patients may be candidates for chemotherapy and/or radiation therapy before or after treatment with AuroLase®.
For more information about the AuroLase clinical study, please contact an Oncology Information Specialist, at (800) 615-3055.